Pediatrics Doctors in Paradise, CA Accepting Medicare
4 Pediatrics doctors found. Showing 1 - 4
 Dr. Samuel A Daniyan, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 6480 Pentz Rd, Suite E, Paradise, CA 95969 Phone: 530-877-5437 |
Mr. James Russell Logan, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 6470 Pentz Rd, Suite A, Paradise, CA 95969 Phone: 530-872-6655 Fax: 530-872-6653 |
 Dr. Susan L Mallory, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 6480 Pentz Rd, Suite E, Paradise, CA 95969 Phone: 530-877-5437 Fax: 530-877-5692 |
Dr. Theodore Zwerdling, MD Pediatrics - Pediatric Hematology-Oncology Medicare: Accepting Medicare Assignments Practice Location: 5125 Skyway, Paradise, CA 95969 Phone: 530-872-2000 Fax: 530-332-1049 |
News Archive
State roundup: Ore. considers rural doc loan repayment
Oregon would restore $4 million in the next biennium to fund a loan repayment program that assists primary health care providers willing to work in rural areas, under a bill being pushed by Sen. Elizabeth Steiner Hayward, D-Beaverton. The program ran for nearly two decades before it was cut in 2009 in the depths of the recession.
Researchers use noninvasive imaging to show variations in renal blood flow
Renal blood flow changes throughout the day in tandem with the body's circadian clock, with the increasing flow during daytime hours and decreasing flow in the evening and into the night.
People without health insurance more likely to forego routine physical exams
The lack of health insurance prompts people to forego routine physical exams and have a reduced awareness of cardiovascular risk factors and is associated with increased rates of stroke and death, researchers have concluded.
Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26-week) toxicology study of CEQ508 – the company's lead drug candidate based on its proprietary tkRNAi technology. This study is designed to enable a Phase II clinical trial slated for 2011. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.
› Verified 7 days ago
Family Medicine
Internal Medicine
Obstetrics & Gynecology
Ophthalmology
Pediatrics
Anesthesiology
Emergency Medicine
Surgery
Psychiatry & Neurology
Orthopaedic Surgery